Showing 4541-4550 of 5328 results for "".
- Topix Pharmaceuticals Introduces All-Trans-Retinol Smoothing Body Lotionhttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-all-trans-retinol-smoothing-body-lotion/2458439/Topix Pharmaceuticals, Inc. has introduced All-trans-Retinol Smoothing Body Lotion, a retinol body treatment featuring layered ingredient technologies and a powerful delivery system for ultimate penetration. Replenix Smoothing Body Lotion contains the maximum dosage of retinol to be safe
- Is Bigger Better? Group Practices Become the New Normhttps://practicaldermatology.com/news/group-practices-are-the-new-norm/2458438/Group physician practices are the new normal, and it seems that dermatologists were ahead of the consolidation curve, according to research in the September 2016 issue of Health Affairs. Researchers examined physician consolidation for both primary care provide
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).
- US FDA Grants Orphan Drug Status to TXA127 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/us-fda-grants-orphan-drug-status-to-txa127-for-recessive-dystrophic-epidermolysis-bullosa/2458442/The U.S. Food and Drug Administration has granted Orphan Drug Status to TXA127 as a potential treatment for the rare genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). TXA127 developer, Tarix Orphan LLC
- Santalis Pharmaceuticals Starts Phase 2 Study of New Sandalwood Oil-based AD Therapyhttps://practicaldermatology.com/news/australias-santalis-pharmaceuticals-starts-phase-2-study-of-new-ad-therapy/2458445/Santalis Pharmaceuticals has enrolled the first patient in a Phase 2 Study of 5% East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). Up to 60 patients aged 3 months to 65 with a clinically stable diagnosis of AD who have a total body surface
- Vivacare and the National Rosacea Society Collaborate on Patient Education Resourcehttps://practicaldermatology.com/news/vivacare-and-the-national-rosacea-society-collaborate-on-patient-education-resource/2458448/Vivacare has launched a new Rosacea Education Kit to support dermatologists in the delivery of care to their rosacea patients. The Kit is available at no cost by enrolling online. Upon enrolling, dermatologists receive
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-pron
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Oculus Innovative Sciences Receives FDA Approval for Post-Dermal-Procedures Producthttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-approval-for-post-dermal-procedures-product/2458455/The FDA awarded Oculus Innovative Sciences, Inc. 510(k) clearance for its new post-dermal-procedures product. Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from postdermal procedures. <